Bio-Rad Laboratories Q3 2025 Earnings Release

Bio-Rad Laboratories, Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported total net sales of $653.0 million, a slight increase of 0.5% compared to the same period in 2024. However, on a currency-neutral basis, sales decreased by 1.7%. The Life Science segment saw a 0.3% increase in net sales, while the Clinical Diagnostics segment reported a 0.6% increase. The company experienced a net loss of $(341.9) million, primarily due to a change in the fair market value of its investment in Sartorius AG. Non-GAAP net income was $60.8 million, or $2.26 per diluted share. Bio-Rad maintained its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of 0 to 1.0% and a non-GAAP operating margin of 12.0 to 13.0%.